- Home
- WTTR vs NRIX Comparison
WTTR vs NRIX Comparison
Compare WTTR & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTTR
- NRIX
- Stock Information
- Founded
- WTTR 2016
- NRIX 2009
- Country
- WTTR United States
- NRIX United States
- Employees
- WTTR N/A
- NRIX N/A
- Industry
- WTTR Oilfield Services/Equipment
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- WTTR Energy
- NRIX Health Care
- Exchange
- WTTR Nasdaq
- NRIX Nasdaq
- Market Cap
- WTTR 922.1M
- NRIX 908.0M
- IPO Year
- WTTR 2017
- NRIX 2020
- Fundamental
- Price
- WTTR $8.78
- NRIX $11.67
- Analyst Decision
- WTTR Strong Buy
- NRIX Strong Buy
- Analyst Count
- WTTR 3
- NRIX 16
- Target Price
- WTTR $14.83
- NRIX $30.44
- AVG Volume (30 Days)
- WTTR 871.5K
- NRIX 893.5K
- Earning Date
- WTTR 07-29-2025
- NRIX 07-10-2025
- Dividend Yield
- WTTR 3.17%
- NRIX N/A
- EPS Growth
- WTTR N/A
- NRIX N/A
- EPS
- WTTR 0.34
- NRIX N/A
- Revenue
- WTTR $1,459,911,000.00
- NRIX $56,417,000.00
- Revenue This Year
- WTTR $2.68
- NRIX $16.69
- Revenue Next Year
- WTTR $5.03
- NRIX N/A
- P/E Ratio
- WTTR $25.43
- NRIX N/A
- Revenue Growth
- WTTR N/A
- NRIX N/A
- 52 Week Low
- WTTR $7.20
- NRIX $8.18
- 52 Week High
- WTTR $15.14
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- WTTR 49.35
- NRIX 53.63
- Support Level
- WTTR $8.56
- NRIX $11.17
- Resistance Level
- WTTR $9.53
- NRIX $12.40
- Average True Range (ATR)
- WTTR 0.29
- NRIX 0.60
- MACD
- WTTR -0.04
- NRIX -0.07
- Stochastic Oscillator
- WTTR 23.08
- NRIX 33.33
About WTTR Select Water Solutions Inc.
Select Water Solutions Inc provides sustainable water and chemical solutions to the energy industry. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. Its reportable segments are Water Services, Water Infrastructure and Chemical Technologies. It generates the majority of its revenue from Water Services segment.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.